eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 02/08/2011
PIL Simulect 10mg powder and solvent for solution for injection or infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/08/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change of manufacturer
Updated on 28/06/2011 and displayed until 02/08/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 16/12/2008 and displayed until 28/06/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 18/04/2008 and displayed until 16/12/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 21/09/2007 and displayed until 18/04/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 17/08/2007 and displayed until 21/09/2007
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
  • Correction of spelling/typing errors
Updated on 08/08/2005 and displayed until 17/08/2007
Reasons for adding or updating:
  • Change to side-effects
Updated on 29/07/2004 and displayed until 08/08/2005
Reasons for adding or updating:
  • Change to Further Information section
Updated on 18/09/2003 and displayed until 29/07/2004
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  basiliximab